or Try an Advanced Search...

    Resistant Prostate Cancer Stocks List

    Symbol Grade Name % Change
    AMGN A Amgen Inc. 11.82
    CRDF D Cardiff Oncology, Inc. -21.43
    EXEL D Exelixis, Inc. -0.99
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes

    Related ETFs - A few ETFs which own one or more of the above listed Resistant Prostate Cancer stocks.

    Symbol Grade Name Weight
    BBH B Market Vectors Biotech ETF 15.08
    IBBQ C Invesco Nasdaq Biotechnology ETF 9.46
    IBB C iShares Nasdaq Biotechnology Index Fund 9.43
    BIS D ProShares UltraShort Nasdaq Biotechnology 8.87
    PBE C PowerShares Dynamic Biotech & Genome 8.27
    View all Resistant Prostate Cancer ETFs...
    Compare ETFs
    Compare BIS to PBE Compare IBB to BIS Compare IBBQ to BIS

        Resistant Prostate Cancer Stocks Recent News

        Date Stock Title
        May 3 AMGN Why Amgen Stock Zoomed Nearly 12% Higher Today
        May 3 AMGN Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
        May 3 AMGN Analyst unveils Amgen stock price target after weight-loss drug data
        May 3 AMGN Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending
        May 3 AMGN Interest rate cuts could switch ‘from stroll to a sprint’ after US jobs surprise
        May 3 AMGN William Blair, Barclays upgrade Amgen following GLP-1 drug update
        May 3 AMGN Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
        May 3 AMGN US STOCKS-Wall St rallies after soft jobs data allays rate jitters
        May 3 AMGN Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
        May 3 AMGN Weight-loss drug competition heats up. Is Wegovy in trouble?
        May 3 AMGN Amgen Inc. (NASDAQ:AMGN) Q1 2024 Earnings Call Transcript
        May 3 AMGN Dow Jones Soars 400 Points As Amgen, Apple Surge; Nvidia Jumps Again, Tempts New Buyers
        May 3 AMGN US STOCKS-Wall St gains after soft jobs data allays rate jitters
        May 3 AMGN Amgen stock rallies 13% on GLP-1 weight-loss drug update
        May 3 AMGN Amgen Knocks Novo Nordisk's Ozempic Stock Rally
        May 3 AMGN Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
        May 3 AMGN Amgen surges over confidence in early obesity drug results
        May 3 AMGN These Two Stocks Are Driving the Dow Friday
        May 3 AMGN Stocks to Watch Friday: Apple, Amgen, Coinbase, Block
        May 3 AMGN Amgen upgraded, Peloton downgraded: Wall Street's top analyst calls
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Prostate Cancer Biotechnology Cancer Drugs Medicine Metastatic Castration Resistant Prostate Cancer Acute Myeloid Leukemia Adenosine Advanced Solid Tumors Antineoplastic Drugs Blood Cells Bone Bone Disease Cancer Care Cancer Treatment Chemotherapy Clinic Clinical Medicine Colorectal Cancer Cyclopropanes
        Resistant Prostate Cancer

        Resistant prostate cancer is a type of prostate cancer that has become resistant to hormone therapy, which is the most common form of treatment for prostate cancer. This type of cancer is more difficult to treat and may require more aggressive treatments such as chemotherapy or radiation therapy.

        Browse All Tags